{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:29:16Z","timestamp":1793806156736,"version":"4.6.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.cpcardiol.2022.101188","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T20:48:22Z","timestamp":1648241302000},"page":"101188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effectiveness and Safety of Oral Anticoagulants in Cardiac Amyloidosis: Lights and Shadows"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4510-6805","authenticated-orcid":false,"given":"Daniela","family":"Di Lisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Di Caccamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Damerino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Portelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Comparato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Di Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Brighina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egle","family":"Corrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo Ruggero","family":"Galassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2022.101188_bib0001","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: recommendations by the international society of amyloidosis (ISA) nomenclature committee","volume":"25","author":"Merrill","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0002","first-page":"19","article-title":"Cardiac amyloidosis: epidemiology, diagnosis and therapy","volume":"19","author":"Papingiotis","year":"2021","journal-title":"E-J Cardiol Pract"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0003","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0004","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1177\/2047487320920756","article-title":"Management of complications of cardiac amyloidosis: 10 questions and answers","volume":"28","author":"Aimo","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0005","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacep.2020.01.004","article-title":"Management of arrhythmias in cardiac amyloidosis","volume":"6","author":"Giancaterino","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0006","first-page":"416","article-title":"Arrhythmias in cardiac amyloidosis: challenges in risk stratification and treatment","volume":"36","author":"Cheung","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0007","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0008","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"Light-chain cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0009","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0010","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0011","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0012","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/ejhf.1285","article-title":"Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure","volume":"20","author":"Gagliardi","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0013","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaccao.2021.09.003","article-title":"Amyloidosis: current chemotherapy and immune therapy treatment strategies","volume":"3","author":"Bianchi","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0014","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0016","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in transthyretin cardiomyopathy Clinical . Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0017","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0018","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1093\/ehjci\/jeab154","article-title":"Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European association of cardiovascular imaging","volume":"23","author":"Smiseth","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0019","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2019.09.056","article-title":"Aortic stenosis and cardiac amyloidosis: JACC review topic of the week","volume":"74","author":"Ternacle","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0020","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/13506129.2011.571319","article-title":"Myocardial infarction with \u201cclean coronaries\u201d caused by amyloid light-chain AL amyloidosis: a case report and literature review","volume":"18","author":"Tsai","year":"2011","journal-title":"Amyloid"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0021","doi-asserted-by":"crossref","first-page":"H2305","DOI":"10.1152\/ajpheart.00503.2011","article-title":"Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins","volume":"301","author":"Migrino","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0022","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tcm.2017.07.004","article-title":"Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment","volume":"28","author":"Siddiqi","year":"2018","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0023","doi-asserted-by":"crossref","DOI":"10.1177\/1179546820963055","article-title":"Ventricular arrhythmias in cardiac amyloidosis: a review of current literature","volume":"14","author":"Khanna","year":"2020","journal-title":"Clin Med Insights Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0024","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/hrt.59.4.498","article-title":"Familial atrial standstill caused by amyloidosis","volume":"59","author":"Maeda","year":"1988","journal-title":"Br Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0025","first-page":"1473","article-title":"No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis","volume":"5","author":"Donnellan","year":"2019","journal-title":"J Am Coll Cardiol EP"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0026","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0002-9149(83)90084-X","article-title":"Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients","volume":"52","author":"Roberts","year":"1983","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0027","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcmg.2021.06.022","article-title":"Clinical importance of left atrial infiltration in cardiac transthyretin amyloidosis","volume":"15","author":"Bandera","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0028","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/eurheartj\/ehx736","article-title":"Left atrial function to identify patients with atrial fibrillation at high risk of stroke: new insights from a large registry","volume":"39","author":"Leung","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0029","first-page":"1128","article-title":"Left atrial structure and function in cardiac amyloidosis","volume":"18","author":"Nochioka","year":"2017","journal-title":"Eur Heart J-Cardiovascular Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0030","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","author":"Feng","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0031","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0032","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"American heart association council on epidemiology and prevention statistics committee and stroke statistics subcommittee. (2019). Heart disease and stroke statistics\u20142019 update: a report from the American heart association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0033","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","article-title":"Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality","volume":"26","author":"Sanchis","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0034","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0035","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.112.107128","volume":"127","author":"Piccini","year":"2013","journal-title":"Circulation."},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0036","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1067\/mhj.2000.109213","article-title":"Incidence of left atrial thrombi in patients in sinus rhythm and with a recent neurologic deficit","volume":"140","author":"Omran","year":"2000","journal-title":"American Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0037","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/hrt.74.5.541","article-title":"Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation","volume":"74","author":"Dubrey","year":"1995","journal-title":"British Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0038","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1378\/chest.102.1.304","article-title":"Amyloid heart disease manifested by systemic arterial thromboemboli","volume":"102","author":"Browne","year":"1992","journal-title":"Chest"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0039","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/jama.1983.03330340064034","article-title":"Bleeding manifestations in 100 patients with amyloidosis","volume":"249","author":"Yood","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0040","doi-asserted-by":"crossref","first-page":"e792","DOI":"10.1161\/STROKEAHA.121.037248","article-title":"Left atrial appendage closure in patients with atrial fibrillation and coexisting cerebral amyloid angiopathy","volume":"52","author":"Blanc","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0041","first-page":"289","article-title":"Clotting alterations in primary systemic amyloidosis","volume":"85","author":"Gamba","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0042","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2516.2005.01125.x","article-title":"Spontaneous major bleeding in acquired factor X deficiency secondary to AL-amyloidosis","volume":"11","author":"Enjeti","year":"2005","journal-title":"Haemophilia"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0043","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1089\/nat.2019.0829","article-title":"Underlying immune disorder may predispose some transthyretin amyloidosis subjects to inotersen-mediated thrombocytopenia","volume":"30","author":"Narayanan","year":"2020","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0044","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0045","first-page":"147","article-title":"Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role","volume":"22","author":"Longhi","year":"2015","journal-title":"Amyloid Int J Exp Clin Investig"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.742428","article-title":"New oral anticoagulants vs. vitamin k antagonists among patients with cardiac amyloidosis: prognostic impact","volume":"8","author":"Cariou","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0047","first-page":"30","article-title":"Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding","volume":"28","author":"Mitrani","year":"2020","journal-title":"Amyloid Int J Exp Clin Investig"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0048","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1016\/S2352-3026(16)30057-6","article-title":"Hokusai-VTE investigators. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial","volume":"3","author":"Raskob","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0049","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0050","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jbspin.2006.12.006","article-title":"Potentiation of fluindione or warfarin by dexamethasone in multiple myeloma and AL amyloidosis","volume":"74","author":"Sellam","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.cpcardiol.2022.101188_bib0051","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jaccao.2021.06.006","article-title":"ATTR amyloidosis: current and emerging management strategies: JACC: cardiooncology state-of-the-art review","volume":"3","author":"Griffin","year":"2021","journal-title":"JACC Cardio Oncol"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622000858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622000858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:39:51Z","timestamp":1758940791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280622000858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0146280622000858"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101188","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and Safety of Oral Anticoagulants in Cardiac Amyloidosis: Lights and Shadows","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101188","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101188"}}